UK pharmaceutical company AstraZeneca (AZ) said in January it will invest USD 15 billion in its Chinese research and production facilities through 2030. The decision puts China on par with the US and Europe as an innovation hub for AZ at a time when US and EU legislation aims to protect their biotech industries from Chinese competition. AZ’s investment includes two strategic labs in China, with staff projected to reach 20,000, overtaking the company’s workforce in the US and UK.
https://merics.org/en/comment/astrazenecas-rd-bet-makes-china-pharma-innovation-hub